Legis Daily

Increasing Access to Biosimilars Act of 2021

USA117th CongressHR-2869| House 
| Updated: 4/29/2021
Tony Cárdenas

Tony Cárdenas

Democratic Representative

California

Cosponsors (2)
Lisa Blunt Rochester (Democratic)Angie Craig (Democratic)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Increasing Access to Biosimilars Act of 2021 This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-6179
Increasing Access to Biosimilars Act of 2020
Apr 28, 2021

Latest Companion Bill Action

S 117-1427
Introduced in Senate
Apr 28, 2021
Introduced in House
Apr 28, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 28, 2021
Referred to the Subcommittee on Health.
Apr 29, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-6179
    Increasing Access to Biosimilars Act of 2020


  • April 28, 2021

    Latest Companion Bill Action

    S 117-1427
    Introduced in Senate


  • April 28, 2021
    Introduced in House


  • April 28, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 28, 2021
    Referred to the Subcommittee on Health.


  • April 29, 2021
    Referred to the Subcommittee on Health.

Health

Related Bills

  • S 117-1427: Increasing Access to Biosimilars Act of 2021
Congressional oversightGovernment studies and investigationsHealth care costs and insuranceMedicarePrescription drugs

Increasing Access to Biosimilars Act of 2021

USA117th CongressHR-2869| House 
| Updated: 4/29/2021
Increasing Access to Biosimilars Act of 2021 This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-6179
Increasing Access to Biosimilars Act of 2020
Apr 28, 2021

Latest Companion Bill Action

S 117-1427
Introduced in Senate
Apr 28, 2021
Introduced in House
Apr 28, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 28, 2021
Referred to the Subcommittee on Health.
Apr 29, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-6179
    Increasing Access to Biosimilars Act of 2020


  • April 28, 2021

    Latest Companion Bill Action

    S 117-1427
    Introduced in Senate


  • April 28, 2021
    Introduced in House


  • April 28, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 28, 2021
    Referred to the Subcommittee on Health.


  • April 29, 2021
    Referred to the Subcommittee on Health.
Tony Cárdenas

Tony Cárdenas

Democratic Representative

California

Cosponsors (2)
Lisa Blunt Rochester (Democratic)Angie Craig (Democratic)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • S 117-1427: Increasing Access to Biosimilars Act of 2021
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Congressional oversightGovernment studies and investigationsHealth care costs and insuranceMedicarePrescription drugs